STXS
What one share of Stereotaxis holds
Electromedical and Electrotherapeutic Apparatus
We believe these benefits can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure.
Stereotaxis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.31 |
|---|---|
| Profit | −$0.24 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.16 |
| Dividends | $0.00 |
| Cash and investments | $0.10 |
| Book value | $0.12 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.47 | −$0.54 | $0.02 | −$0.32 | — | −$0.96 |
| 2017 | $1.38 | −$0.32 | $0.00 | −$0.21 | — | — |
| 2018 | $0.56 | −$0.03 | $0.01 | −$0.05 | — | $0.02 |
| 2019 | $0.46 | −$0.10 | $0.00 | −$0.07 | — | $0.33 |
| 2020 | $0.37 | −$0.11 | $0.00 | −$0.05 | — | $0.47 |
| 2021 | $0.46 | −$0.16 | $0.02 | −$0.06 | — | $0.45 |
| 2022 | $0.37 | −$0.26 | $0.03 | −$0.14 | — | $0.35 |
| 2023 | $0.33 | −$0.27 | $0.00 | −$0.12 | — | $0.20 |
| 2024 | $0.32 | −$0.30 | $0.00 | −$0.10 | — | $0.07 |
| 2025 | $0.36 | −$0.25 | $0.00 | −$0.15 | — | $0.14 |